Obstetrics and Gynecology Interventional Clinical Trials

Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia

• The primary objective is to evaluate if green tea extract (Polyphenon E) as compared to placebo will stop cervical cancer from forming in patients with human papillomavirus and low-grade cervical intraepithelial neoplasia.
• Subjects with human papillomavirus (HPV) expression and low-grade cervical intraepithelial neoplasia (CIN 1)
• Patients receive oral green tea extract or placebo once daily for 16 weeks in the absence of unacceptable toxicity.
• The primary investigator is David Greenspan, MD
• The study coordinator is Blanca-Flor Jimenez, MAOM (602) 344-5439

Early Detection of Resistance to Standard Anti-Cancer Drugs in the Treatment of Ovarian Cancer

• The primary objective is to test for genomic abnormalities in the primary tumors associated with the development of resistance to the platinum and taxane drug regimens using array-based tumor profiling.
• Subjects with ovarian cancer
• Collect and preserve primary ovarian cancer tissue, a sample of metastatic tumor tissue, if present, uninvolved ovarian tissues where possible, and patient blood (serum and whole blood) from consenting participants.
l
• Subjects to return to MIHS for a blood draw at 3, 6, 9, 12, and 24 months from the initial diagnosis
• The primary investigator is David Greenspan, MD
• The study coordinator is Blanca-Flor Jimenez, MAOM (602) 344-5439

Multicentre randomised controlled trial (RCT) comparing planned caesarean section (CS) and planned vaginal birth (VB) for twin pregnancies to determine adverse perinatal and maternal outcome

• The primary objective is to evaluate if planned CS decreases each twin perinatal/neonatal mortality and/or serious neonatal morbidity.
• Women with a twin pregnancy at 32-38 weeks gestation, who meet the selection criteria and consent to participate in the trial, will be randomized for VB or CS birth
• Following discharge from hospital after the birth, women and infants will be followed for 2 years. Questionnaires at 3 months and 2 years following delivery will be completed by mail, if possible, otherwise by telephone or during a clinic or home visit
• The primary investigator is Dean Coonrod, MD
• The study coordinator is Blanca-Flor Jimenez, MAOM (602) 344-5439

The study coordinator is Blanca-Flor Jimenez, MAOM (602) 344-5439

 

 

 

 

Last updated on December 16, 2009